US Bancorp DE Trims Stock Holdings in Guardant Health, Inc. $GH

US Bancorp DE lowered its holdings in Guardant Health, Inc. (NASDAQ:GH) by 7.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 34,046 shares of the company’s stock after selling 2,652 shares during the period. US Bancorp DE’s holdings in Guardant Health were worth $1,772,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Signaturefd LLC boosted its holdings in Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after purchasing an additional 213 shares during the last quarter. SVB Wealth LLC bought a new position in Guardant Health during the 1st quarter worth approximately $54,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Guardant Health during the 1st quarter worth approximately $97,000. CWM LLC lifted its holdings in Guardant Health by 180.3% during the 1st quarter. CWM LLC now owns 2,296 shares of the company’s stock worth $98,000 after buying an additional 1,477 shares during the last quarter. Finally, Nkcfo LLC bought a new position in Guardant Health during the 1st quarter worth approximately $107,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Activity at Guardant Health

In related news, Director Medina Manuel Hidalgo sold 2,165 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $54.16, for a total value of $117,256.40. Following the sale, the director directly owned 851 shares in the company, valued at $46,090.16. This trade represents a 71.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Helmy Eltoukhy sold 300,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total value of $17,835,000.00. Following the completion of the sale, the chief executive officer owned 2,123,499 shares in the company, valued at approximately $126,242,015.55. This represents a 12.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 302,549 shares of company stock worth $17,975,121. 6.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

GH has been the topic of a number of research analyst reports. BTIG Research set a $80.00 target price on Guardant Health in a report on Thursday, September 25th. Wells Fargo & Company initiated coverage on Guardant Health in a report on Monday, September 22nd. They set an “overweight” rating and a $72.00 target price on the stock. Scotiabank increased their target price on Guardant Health from $57.00 to $60.00 and gave the stock a “sector outperform” rating in a report on Thursday, July 31st. Guggenheim increased their target price on Guardant Health from $56.00 to $67.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Finally, Evercore ISI increased their target price on Guardant Health from $60.00 to $68.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Twenty-three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $65.86.

Guardant Health Price Performance

GH opened at $64.19 on Thursday. Guardant Health, Inc. has a 12 month low of $20.14 and a 12 month high of $68.00. The stock has a market cap of $8.01 billion, a P/E ratio of -19.16 and a beta of 1.53. The stock’s 50 day moving average price is $60.50 and its 200 day moving average price is $50.52.

Guardant Health (NASDAQ:GH) last posted its earnings results on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.08. The business had revenue of $232.09 million during the quarter, compared to analyst estimates of $211.19 million. During the same quarter in the prior year, the business earned ($0.84) earnings per share. The firm’s revenue was up 31.0% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. Equities analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.